Reuters2026-10-062026-10-062026-03-19Reuters. (2026). How India's weight-loss drugs could reshape global obesity fight. Daily Monitor.https://bdears.busitema.ac.ug/handle/123456789/10202Newspaper ArticleIndia could soon see wider access to weight-loss drugs following the expiry of a key patent, a move expected to drive down prices and trigger competition among local pharmaceutical firms. The patent on semaglutide-the active ingredient behind Novo Nordisk's popular drugs Wegovy and Ozempic-expires in India this week.enArticle